Komori
Presentation materials for financial results4577Daito Pharmaceutical Co.,Ltd.Pharmaceuticals

Briefing Materials on Financial Results for the Third Quarter of the Fiscal Year Ending May 2026

In the third quarter, net sales edged up year on year, while operating income, ordinary income and net income rose significantly. In light of profit progress exceeding 90%, among other factors, the full-year net sales forecast was revised downward, while the profit forecasts were revised upward.

Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
300
¥ million (full-year operating profit forecast revision)
Wording
Definitive
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsThird quarter of the fiscal year ending May 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥36,732 million+0.3%
Operating profit¥2,751 million+47.2%
Ordinary income¥2,974 million+46.2%
Net income¥2,267 million+86.2%
Full-year earnings forecast
Net Sales
¥51,000 million
EBITDA
¥7,750 million
Operating profit
¥3,300 million
Ordinary income
¥3,500 million
Profit attributable to owners of the parent
¥2,500 million
EPS
¥84.38
Dividend
¥40 per share
Research and development costs
¥2,200 million
Depreciation and amortization
¥4,450 million
Capital expenditures
¥4,000 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。Profit progress exceeded 90% (progress by line item: Not disclosed)
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Changes in net sales, product mix, etc.¥1 million
  • Impact of the temporary shutdown of the Shimo-Okui Plant, etc.¥-273 million
  • Foreign exchange impact¥36 million
  • Impact of inventory valuation, etc.¥550 million
  • Depreciation¥-94 million
  • Personnel expenses¥-76 million
  • Research and development costs¥353 million
  • Utilities expenses¥143 million
  • Other expenses, etc.¥242 million
New initiatives
  • Transfer of the marketing authorizations for Ono Pharmaceutical's Opalmon Tablets and Prostandin Ointment, consolidation of manufacturing sites, and exports to Thailand
  • Agreement with Toyochem, a member of the artience Group, on the joint development, manufacture and sale of high-value-added formulations
  • Nobelpharma's start of the Phase III trial of its ubiquinol-containing formulation NPC-29 and administration of the investigational drug
Key KPIsA metric the company considers important as a management benchmark.
  • EBITDA¥6,025 million+18.7%
  • EPS¥76.53+92.0%
  • Operating cash flow¥8,022 million+104.4%
Medium-term management plan targets
Progress on DTP2027 and achievement of the KGI for the final year of the current medium-term management plan are discussed (target value and target year details: Not disclosed)
Capital expenditures
¥3,516 million
Annual Dividend
¥40 per share
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredThird quarter of the fiscal year ending May 2026
Net Sales¥36,732 million (YoY +0.3%)
Operating profit¥2,751 million (YoY +47.2%)
Ordinary income¥2,974 million (YoY +46.2%)
Net income¥2,267 million (YoY +86.2%)
Full-year earnings forecastNet Sales ¥51,000 million / EBITDA ¥7,750 million / Operating profit ¥3,300 million / Ordinary income ¥3,500 million / Profit attributable to owners of the parent ¥2,500 million / EPS ¥84.38 / Dividend ¥40 per share / Research and development costs ¥2,200 million / Depreciation and amortization ¥4,450 million / Capital expenditures ¥4,000 million
Progress against full-year forecastProfit progress exceeded 90% (progress by line item: Not disclosed)
Breakdown of Factors Affecting the ChangeFactors Changes in net sales, product mix, etc. / Amount ¥1 million, Factors Impact of the temporary shutdown of the Shimo-Okui Plant, etc. / Amount ¥-273 million, Factors Foreign exchange impact / Amount ¥36 million, Factors Impact of inventory valuation, etc. / Amount ¥550 million, Factors Depreciation / Amount ¥-94 million, Factors Personnel expenses / Amount ¥-76 million, Factors Research and development costs / Amount ¥353 million, Factors Utilities expenses / Amount ¥143 million, Factors Other expenses, etc. / Amount ¥242 million
Key KPIsEBITDA ¥6,025 million (YoY +18.7%), EPS ¥76.53 (YoY +92.0%), Operating cash flow ¥8,022 million (YoY +104.4%)
Medium-term management plan targetsProgress on DTP2027 and achievement of the KGI for the final year of the current medium-term management plan are discussed (target value and target year details: Not disclosed)
Annual Dividend¥40 per share
Capital expenditures¥3,516 million
New initiativesTransfer of the marketing authorizations for Ono Pharmaceutical's Opalmon Tablets and Prostandin Ointment, consolidation of manufacturing sites, and exports to Thailand, Agreement with Toyochem, a member of the artience Group, on the joint development, manufacture and sale of high-value-added formulations, Nobelpharma's start of the Phase III trial of its ubiquinol-containing formulation NPC-29 and administration of the investigational drug
Items this document does not state (17)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In the results to date, the main factors behind the increase in profit were a higher formulated-product ratio, lower valuation losses on long-outstanding inventory, lower research and development expenses, and lower SG&A expenses resulting from the thorough implementation of Smart Spending. The upward revision to the full-year forecasts was attributed to the higher formulated-product ratio, lower-than-expected depreciation and amortization expenses following a change in accounting policy, and lower-than-expected research and development expenses due to revisions to the development plan and timing shifts in bioequivalence studies.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Briefing Materials on Financial Results for the Third Quarter of the Fiscal Year Ending May 2026 | Daito Pharmaceutical Co.,Ltd. (4577) timely disclosure | Komori